Author: Michael Millhollen
4 Ways De-Risking Maximizes Compound Value
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in...
Meet the Scientist: Alex Wakefield
In this month’s installment of our Meet the Scientist series we wanted to feature one of our team of talented...
2021 Service Expansions: Microsomal Protein Binding and Red Blood Cell Partitioning
Over the course of 2021, we expanded access to two important and related study offerings at our US laboratory headquarters....
Meet the Scientists: Program Execution
In this installment of our Meet the Scientist series, we asked several members from various areas of our Program Execution...
Meet the Scientists: Analytical Services’ Chandra Kollu & Nadya Galeva
This month we’re featuring two of the experts in our analytical services department: Senior Scientist Chandra Kollu and Mass Spectrometry...
ADME/PK & DDI Best Practices Industry Survey Results & Infographic
With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies...
Guide to When & Why to Evaluate ADME/DMPK & Drug-Drug Interactions Available
In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with...
Why Switch to Hepatocyte Pellets?
You may have heard about the patented CryostaX® format of hepatocyte pellets, but do you know why XenoTech and countless other researchers have made the…
XenoTech Named Most Innovative Drug Development Solutions Provider – USA 2020
The 2020 Technology Innovator Awards returns for its fifth year “to reward those talented and dedicated individuals and firms working...
COVID-19 Updates
As a global Life Sciences and Healthcare company, XenoTech recognizes the seriousness of the Coronavirus Pandemic. We are constantly monitoring...
Meet the Scientist: Andrea Wolff
At XenoTech, we pride ourselves on our 3S Principles – the values and standards that guide our businesses and shape...
Meet the Scientist: Mark Horrigan
Continuing our effort to put faces to the names of some of the scientists you interact with at XenoTech, we...
XenoTech Named Best In Vitro Drug CRO 2019
XenoTech has been named the Best In Vitro Drug CRO in the 2019 Healthcare & Pharmaceutical Awards. From the release:...
XenoTech Named a 2019 Top-Performing Provider on Science Exchange
Science Exchange stated, “Discovery research programs at growing biotech companies are demanding—R&D leaders must balance the need to innovate with...
XenoTech Named Best for Drug Candidate Evaluations 2019, Leading Providers of Pharmaceuticals Safety Testing
XenoTech has been named the Best for Drug Candidate Evaluations 2019 as well as in the Leading Providers of Pharmaceuticals...
Disease-State Test Systems
XenoTech has been working with and supplying reagents for the pre-clinical ADME field for well over two decades. Years of...
5 Keys to Set Your Contract Research Organization (CRO) Collaboration Up for Success
Over the past 25 years of performing ADME/DMPK/DDI contract research, we’ve learned some key strategies to maximize the efficiency and effectiveness...
Holiday CSR Activities
XenoTech understands that a better future starts with our actions today, and encourages its global family to remain focused on...
October Presentations on In Vitro Effects of Biologics on CYP Enzymes and Regulatory DDI Guidances
On Oct. 15th at the Peptide ADME Discussion Group Workshop in Gothenburg, Sweden, Dr. Brian Ogilvie presented on In vitro Direct and Cytokine-Mediated...
New Rodent, Monkey CryostaX Hepatocytes Featured in Industry News
Following XenoTech’s announcement XenoTech Adds Monkey, Rodent Hepatocytes to Patented CryostaX Product Line, Anticipates the End of Traditionally Cryopreserved Hepatocytes, various...
Challenges & Solutions in Today’s In Vitro Transporter Research
Transporters are membrane-bound proteins that govern the passage of drugs into and out of cells. These gatekeeper proteins can be...